MPs call for brand-only prescribing for biotech drugs

摘要

Medicines derived through biotechnology should always be prescribed by brand,rather than by their generic name,a review by a Parliamentary panel published this week has recommended.The panel examined the issues surrounding the introduction of follow-on products in the wake of the expiry of the patents of biotechnology products.Unlike generic copies of chemical drugs,biosimilar medicines are not identical to originator products.